No Data
No Data
Kang Yuan Pharmaceuticals (301281.SZ) has partnered with Peking Nuokangda Pharmaceutical Technology Co., Ltd on the Vitamin A Palmitate Active Pharmaceutical Ingredient project.
Koyuan Pharmaceutical (301281.SZ) stated on the investor interaction platform on August 8 that the company is cooperating with Peking Nokonda Pharmaceutical Technology Co., Ltd. on the project of vitamin A palmitate active pharmaceutical ingredient, and the project is currently under development.
Keyuan Pharmaceutical (301281.SZ) appointed Jiang Hongsheng as the company's general manager
Zhitong Finance App News, Keyuan Pharmaceutical (301281.SZ) announced that the company's board of directors recently received a written resignation report from Wang Jianwei, general manager of the company. Wang Jianwei applied to resign as general manager of the company due to personal reasons. After resigning, he will no longer hold any position in the company. Wang Jianwei's resignation report took effect on the day it was delivered to the company's board of directors. Furthermore, the board of directors of the company reviewed and passed the “Proposal on the Appointment of the Company's General Manager” and agreed to appoint Jiang Hongsheng as the company's general manager.
Keyuan Pharmaceutical (301281.SZ) plans to pay 3 yuan for 10 shares to be deducted from interest on April 30
Keyuan Pharmaceutical (301281.SZ) announced that the company's 2023 equity distribution plan: to all shareholders for every 10...
Keyuan Pharmaceutical (301281.SZ): Overseas sales revenue in 2023 accounted for about 21.80% of the company's total revenue
Gelonghui, April 17 | Keyuan Pharmaceutical (301281.SZ) said on the investor interactive platform that our company responds positively to the national foreign trade policy and continues to promote the market globalization strategy. According to the company's 2023 annual report data, overseas sales revenue accounts for about 21.80% of the company's total revenue.
Keyuan Pharmaceutical (301281.SZ): Gliclazide API is the single champion product in the Shandong manufacturing industry
Gelonghui, April 17 | Keyuan Pharmaceutical (301281.SZ) said on the investor interactive platform that the company's product Gliclazide API is the single champion product in the Shandong manufacturing industry.
Keyuan Pharmaceutical (301281.SZ): The company's product OR10154 is used in L'Oréal sunscreen products
Gelonghui, April 17 | Keyuan Pharmaceutical (301281.SZ) said on the investor interactive platform that the company is currently a supplier of L'Oréal and uses the CDMO model. The company's product OR10154 is used in L'Oréal sunscreen products and is an effective sunscreen ingredient in sunscreen products. Based on years of technology accumulation and cooperative relationships with customers, the company gives full play to the company's production, R&D and environmental protection advantages in the field of chemical raw materials, deeply exploits current international customers, steadily expands the CDMO business, and strives to make the CDMO business one of the troika for the company's performance growth.
No Data